pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Exondys 51
drug
save

eteplirsen

Marketedupdated 3mo ago
by $SRPT Sarepta Therapeutics, Inc.
Approved
community read0 votes

indications

investigational
Duchenne Muscular Dystrophy

all catalysts(0)

nothing on the calendar yet

Trials studying eteplirsen

  • phase3A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)active not recruitingn=160
  • —A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practiceenrolling by invitationn=300
  • phase2Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Expansion (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatmentterminatedn=62
  • phase2A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications.completedn=3
  • phase2A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) Who Have Completed Study 4658-102 (NCT03218995)terminatedn=15

Patent cliff

source: FDA Orange Book
first barrier falls
Oct 27, 2028
~2.2 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (10)

  • Mar 14, 2034method-of-use (U-1918)US 10337003
  • Mar 14, 2034method-of-use (U-1918)US 10337003
  • Mar 14, 2034method-of-use (U-1918)US 10364431
  • Mar 14, 2034method-of-use (U-1918)US 10364431
  • Mar 14, 2034method-of-use (U-1919)US 9506058
  • Mar 14, 2034method-of-use (U-1919)US 9506058
  • Feb 2, 2029formulationUS RE477692.5y
  • Feb 2, 2029formulationUS RE477692.5y
  • Oct 27, 2028method-of-use (U-2097)US RE484682.2y
  • Oct 27, 2028method-of-use (U-2097)US RE484682.2y

News(1)

  • Dyne gets early 2027 decision date for Duchenne therapy, analysts expect ‘smooth’ review
    If approved, Dyne Therapeutics’ zeleciment rostudirsen could “capture the majority” of the exon-51 Duchenne muscular dystrophy market, given its better efficacy and dosing profile versus Sarepta Th…
    biospace · 24d ago
brand
Exondys 51
generic
eteplirsen
indication
Duchenne Muscular Dystrophy
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 15m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?